Nov 02,2023 TOP STORY

Insulet Reports Third Quarter 2023 Revenue Increase of 27% Year-Over-Year

Insulet Corporation announced financial results for the three months ended September 30, 2023. Third quarter 2023 revenue of the company is reported as $432.7 million, up 27.0%, or 25.1% in constant currency, compared to $340.8 million in the prior year. Total Omnipod revenue was $422.0 million, grew by 29.4%, or 27.5% in constant currency. During this quarter, the Company commercially launched Omnipod 5 in Germany, their second European Omnipod 5 launch, with the intent to launch Omnipod 5 more broadly across Europe starting in 2024. Also they stated the planning for U.S. limited market release of Omnipod 5 integrated with Dexcom’s G7 sensor in early 2024.

View Analyst & Ambassador Comments
Go to original news
Nov 02,2023 TOP STORY

Sibionics wins CE mark for GS1 CGM System

Chinese company Sibionics has obtained a CE Mark for its GS1 continuous glucose monitoring system (CGM), a wearable device that uses an under-the-skin sensor to measure glucose levels in real-time, transmitting the information to a linked handset or mobile phone. The GS1 CGM offers users 14 days of continuous glucose monitoring without the need for frequent calibration. It allows users to transmit glucose data to monitoring devices or mobile apps and generate professional reports.  An additional feature of the system supports data sharing with friends and family and integrates the ProView remote access platform for healthcare providers to monitor and intervene. The GS1 CGM received marketing approval in China in 2021, and the company claims that it is the first blood-glucose meter without the need for finger blood calibration. 

REGULATORY CE MARK

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 30,2023

Senseonics Holdings, Inc Schedules Third Quarter 2023 Earnings Release

Senseonics announced that it plans to release its third quarter 2023 financial results after market close on Thursday, November 9, 2023. Management will hold a conference call to review the Company’s third quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.

View Analyst & Ambassador Comments
Go to original news
Nov 02,2023 TOP STORY

DarioHealth Reports Third Quarter 2023 Financial and Operating Results

DarioHealt reported financial results for the third quarter 2023 and provided a corporate and commercial update. Revenues for Q3 2023 were $3.52 million, a 46.7% decrease from $6.6 million for the Q3 2022, and a decrease of 42.8% from $6.15 million for Q2 2023. The decrease in revenues for Q3 2023, as compared to Q3 2022, was claimed to be resulted mainly from a reduction in revenues derived from the Company's strategic partnerships that are included in the revenues from services and the B2C channel. Net loss was $15.7 million in the Q3 2023, an increase of $100,000, or 0.6%, compared to a net loss of $15.6 million in the Q3 2022, and a decrease of $0.9 million, or 5.1%, compared to $16.6 million for the Q2 2023. Additionally, revenues for the nine months ended September 30, 2023, were $16.74 million, a 19.7% decrease from $20.85 million for the nine months ended September 30, 2022.

View Analyst & Ambassador Comments
Go to original news
Oct 31,2023

Business vs After-Hours Use of an Artificial Intelligence–Powered Digital Health Platform Among Insured Patients

Digital health programs powered by artificial intelligence (AI) offer patients and clinicians the convenience of accessing and delivering health care services remotely, enabling patients to manage their health from anywhere, at any time. However, there is limited evidence of when patients engage with digital health. This cross-sectional study assessed utilization patterns of a commercially available digital health platform. The primary hypothesis was that members would engage more often with AI-powered coaching after hours than during business hours. This study leveraged data from 79?437 members who participated in 1?464?752 unique coaching sessions from January 2022 to April 2023 on a platform called Lark that offers chronic disease prevention and management programs covered by members’ insurance. They analyzed the percentage of coaching sessions that occurred by hour Monday to Sunday. The findings of this study suggest that many people seek support for prevention and management of their health conditions after standard business hours.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 30,2023

Acoustic Analysis and Prediction of Type 2 Diabetes Mellitus Using Smartphone-Recorded Voice Segments

The aim of this study is to investigate the potential of voice analysis as a prescreening or monitoring tool for type 2 diabetes mellitus (T2DM) by examining the differences in voice recordings between nondiabetic and T2DM individuals. Total 267 participants diagnosed as nondiabetic (79 women and 113 men) or T2DM (18 women and 57 men) on the basis of American Diabetes Association guidelines were recruited in India between August 30, 2021 and June 30, 2022. Using a smartphone application, participants recorded a fixed phrase up to 6 times daily for 2 weeks, resulting in 18,465 recordings. Fourteen acoustic features were extracted from each recording to analyze differences between nondiabetic and T2DM individuals and create a prediction methodology for T2DM status. Overall, vocal changes were detected in individuals with T2DM compared with those without T2DM. Voice analysis has shown potential as a prescreening or monitoring tool for T2DM, particularly when combined with other risk factors associated with the condition.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Oct 31,2023 TOP STORY

Sugar.fit Raises $11 Mn Funding To Help People Combat Diabetes

Healthtech startup Sugar.fit has raised $11 Mn in Series A funding led by MassMutual Ventures. The round saw participation from existing investors including Cure.fit, Tanglin Venture Partners, and Endiya Partners. The healtech startup will use the fresh capital to expand its product offering, launch an offline presence, and accelerate research and development in the field of diabetes management, stepping up the brand’s footprint and growth. Founded in 2021 by Madan Somasundaram and Shivtosh Kumar, Sugar.fit seeks to manage and reverse Type 2 and pre-diabetes through a holistic, science-backed, and data-driven digital health experience.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Nov 01,2023 TOP STORY

Bayer launches support tool for diabetic kidney disease

Bayer has launched a digital patient support package in England designed to help people with type 2 diabetes look after the health of their kidneys and avoid progression to chronic kidney disease (CKD). The package, dubbed My Kidney Assistan, is being rolled out initially to a cohort of diabetes patients in England, including some who have already been diagnosed with CKD. My Kidney Assistant allows users to log health data like blood pressure, cholesterol, and blood sugar levels, as well as test results and how well they are adhering to drug treatments. They can also set personal goals – including weight loss, activity levels, and alcohol reduction – and get reminders to take their medication.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 31,2023

Egyptian health tech Almouneer raises $3.6M to scale its platform for treating diabetes and obesity

Almouneer, an Egyptian healthtech company, has raised $3.6 million in seed funding to support the development and expansion of its platform for treating diabetes and obesity. The funding round was led by Dubai-based Global Ventures, with participation from other international investors, including Proparco, Digital Africa via the Bridge Fund, Wrightwood Investments, and others. Almouneer’s platform, DRU, is a patient-centric, digitally-enabled lifestyle and diabetes management platform. It allows patients to upload their medical records, access their latest medical data and current medications, connect with doctors and healthcare personnel via chat or phone, and subscribe to personalised treatment and nutrition plans.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES